Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment |
| |
Affiliation: | 1. Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg;2. Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany |
| |
Abstract: | |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|